LONDON, ONTARIO--(MARKET WIRE)--Sep 11, 2007 -- Stellar Pharmaceuticals Inc., (CDNX:SLX.V - News)(OTC BB:SLXCF.OB - News) (“Stellar” or the “Company”), a Canadian pharmaceutical developer and marketer of high quality, cost-effective products for select health care markets, today announced it has agreed to a settlement of its previously disclosed dispute with its European licensee of Uracyst products, G. Pohl-Boskamp GmbH & Co. (“Pohl-Boskamp”).
